Sagimet Biosciences, Inc. Class A (SGMT) Stock Forecast & Price Target

Compare

1,518 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SGMT Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Sagimet

Biosciences, Inc. Class A

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SGMT Stock 12 Month Forecast

Average Price Target

$27.00

▲(339.02% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Sagimet Biosciences, Inc. Class A in the last 3 months. The average price target is $27.00 with a high forecast of $29.00 and a low forecast of $25.00. The average price target represents a 339.02% change from the last price of $6.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","30":"$30","8.25":"$8.25","15.5":"$15.5","22.75":"$22.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.25,15.5,22.75,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.25,9.846153846153847,11.442307692307693,13.038461538461538,14.634615384615385,16.230769230769234,17.826923076923077,19.423076923076923,21.01923076923077,22.615384615384617,24.211538461538463,25.80769230769231,27.403846153846153,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.25,9.692307692307692,11.134615384615385,12.576923076923077,14.01923076923077,15.461538461538462,16.903846153846153,18.346153846153847,19.78846153846154,21.23076923076923,22.673076923076923,24.115384615384613,25.557692307692307,{"y":27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.25,9.538461538461538,10.826923076923077,12.115384615384617,13.403846153846153,14.692307692307693,15.980769230769232,17.26923076923077,18.557692307692307,19.846153846153847,21.134615384615387,22.423076923076923,23.711538461538463,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.16,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$29.00

Average Price Target$27.00

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Edward Nash

Canaccord Genuity

$28

Buy

355.28%

Upside

Reiterated

09/18/25

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from Canaccord Genuity

Thomas Smith

Leerink Partners

$26

Buy

322.76%

Upside

Reiterated

08/18/25

Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

08/18/25

Promising Growth Potential of Sagimet Biosciences: Buy Rating Justified by Strategic Trials and Strong Financial Position

Debanjana Chatterjee

JonesTrading

$27→$26

Buy

322.76%

Upside

Reiterated

08/17/25

Analysts' Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE)Post these updates, our DCF-based PT is at $26, slightly down from $27.

Jay Olson

Oppenheimer

$25

Buy

306.50%

Upside

Reiterated

08/15/25

Sagimet Biosciences, Inc. Class A (SGMT) Gets a Buy from Oppenheimer

Brandon Folkes

H.C. Wainwright

$29

Buy

371.54%

Upside

Reiterated

08/15/25

Sagimet Biosciences: Promising Advancements in FASN Inhibitor Platform and Strategic Growth Initiatives Justify Buy Rating

Yun Zhong

Wedbush

$28

Buy

355.28%

Upside

Reiterated

08/15/25

Promising Potential of Sagimet Biosciences' FASN Inhibitors Drives Buy Rating

Yasmeen Rahimi

Piper Sandler

$67

Buy

989.43%

Upside

Reiterated

06/17/25

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)

Ed Arce

Westpark Capital

$32

Buy

420.33%

Upside

Reiterated

03/11/25

Promising Pipeline and Positive Trial Data Support Buy Rating for Sagimet Biosciences

Jonathan Wolleben

Citizens JMP

$31

Buy

404.07%

Upside

Reiterated

03/11/25

Sagimet Biosciences' Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567

Eliana Merle

UBS

$12

Buy

95.12%

Upside

Initiated

11/11/24

Sagimet Biosciences: Promising Drug Denifanstat and Market Potential Drive Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Edward Nash

Canaccord Genuity

$28

Buy

355.28%

Upside

Reiterated

09/18/25

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from Canaccord Genuity

Thomas Smith

Leerink Partners

$26

Buy

322.76%

Upside

Reiterated

08/18/25

Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

08/18/25

Promising Growth Potential of Sagimet Biosciences: Buy Rating Justified by Strategic Trials and Strong Financial Position

Debanjana Chatterjee

JonesTrading

$27→$26

Buy

322.76%

Upside

Reiterated

08/17/25

Analysts' Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE)Post these updates, our DCF-based PT is at $26, slightly down from $27.

Jay Olson

Oppenheimer

$25

Buy

306.50%

Upside

Reiterated

08/15/25

Sagimet Biosciences, Inc. Class A (SGMT) Gets a Buy from Oppenheimer

Brandon Folkes

H.C. Wainwright

$29

Buy

371.54%

Upside

Reiterated

08/15/25

Sagimet Biosciences: Promising Advancements in FASN Inhibitor Platform and Strategic Growth Initiatives Justify Buy Rating

Yun Zhong

Wedbush

$28

Buy

355.28%

Upside

Reiterated

08/15/25

Promising Potential of Sagimet Biosciences' FASN Inhibitors Drives Buy Rating

Yasmeen Rahimi

Piper Sandler

$67

Buy

989.43%

Upside

Reiterated

06/17/25

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)

Ed Arce

Westpark Capital

$32

Buy

420.33%

Upside

Reiterated

03/11/25

Promising Pipeline and Positive Trial Data Support Buy Rating for Sagimet Biosciences

Jonathan Wolleben

Citizens JMP

$31

Buy

404.07%

Upside

Reiterated

03/11/25

Sagimet Biosciences' Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567

Eliana Merle

UBS

$12

Buy

95.12%

Upside

Initiated

11/11/24

Sagimet Biosciences: Promising Drug Denifanstat and Market Potential Drive Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sagimet Biosciences, Inc. Class A

1 Month

xxx

Success Rate

3/6 ratings generated profit

Average Return

+5.85%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +5.85% per trade.

3 Months

xxx

Success Rate

3/6 ratings generated profit

Average Return

+51.12%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +51.12% per trade.

1 Year

Ed ArceWestpark Capital

Success Rate

5/6 ratings generated profit

Average Return

+72.20%

reiterated a buy rating 6 months ago

Copying Ed Arce's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +72.20% per trade.

2 Years

xxx

Success Rate

6/6 ratings generated profit

Average Return

+83.67%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +83.67% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SGMT Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SGMT has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SGMT average Analyst price target in the past 3 months is 27.00.

Each month's total comprises the sum of three months' worth of ratings.

SGMT Financial Forecast

SGMT Earnings Forecast

Next quarter’s earnings estimate for SGMT is -$0.39 with a range of -$0.58 to -$0.33. The previous quarter’s EPS was -$0.32. SGMT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.33% of the time in the same period. In the last calendar year SGMT has Outperformed its overall industry.

SGMT Sales Forecast

Next quarter’s sales forecast for SGMT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SGMT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 44.14% of the time in the same period. In the last calendar year SGMT has Preformed in-line its overall industry.

SGMT Stock Forecast FAQ

What is SGMT’s average 12-month price target, according to analysts?

Based on analyst ratings, Sagimet Biosciences, Inc. Class A’s 12-month average price target is 27.00.

What is SGMT’s upside potential, based on the analysts’ average price target?

Sagimet Biosciences, Inc. Class A has 339.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SGMT a Buy, Sell or Hold?

Sagimet Biosciences, Inc. Class A has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Sagimet Biosciences, Inc. Class A’s price target?

The average price target for Sagimet Biosciences, Inc. Class A is 27.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $29.00 ,the lowest forecast is $25.00. The average price target represents 339.02% Increase from the current price of $6.15.

What do analysts say about Sagimet Biosciences, Inc. Class A?

Sagimet Biosciences, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of SGMT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sagimet Biosciences, Inc. Class A (SGMT) Stock Forecast & Price Target

SGMT Analyst Ratings

SGMT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sagimet Biosciences, Inc. Class A

SGMT Analyst Recommendation Trends

SGMT Financial Forecast

SGMT Earnings Forecast

SGMT Sales Forecast

SGMT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts